With U.S. firms expected to struggle when it comes to expanding earnings in the coming quarters, Goldman Sachs’ chief equity analyst is recommending that investors focus on companies with higher expected return-on-equity (ROE) growth, noting that “Firms with the fastest expected ROE have outperformed year-to-date as the pace of economic growth has slowed.” Which companies have the highest expected ROE growth, according to Goldman’s analysis? CLICK HERE.
Dividend-paying stocks outperform the market – and companies that initiate or increase their dividends outperform steady payers. As such, the author of today’s article advises that “investors should pay attention to companies that can continuously grow their dividends, as that improves the probability that they can outperform the market.” He proceeds to highlight his top dividend growth stock for investors to consider this month – a midstream master limited partnership with 22 straight quarterly dividend increases and which, thanks in part to a dramatic transformation in the past year, is positioned to continue raising payouts for years to come. CLICK HERE.
While most stocks currently receiving new Buy or Outperform analyst ratings have upside potential of 8% to 10%, the author of today’s article reminds the reader that “There is another type of Buy rating that is far more speculative, one in which the projected upside can be 50%, 100% or exponentially higher.” He proceeds to highlight five biotech stocks that currently fall into this category – with upside potential ranging from 100% to 400%. For these five biotechs – as well as a couple of runners-up with under-100% (but still high) upside potential – CLICK HERE.
Each of the five stocks highlighted in today’s article is low-priced (trading at less than $10 a share), pays a dividend (up to more than 5%) and carries the highest analyst ratings, with the author noting that “In general, studies find that the strongest ranked buys do outperform the market, on average.” For these five stocks that passed the author’s screen – a semiconductor company, several financial services providers, and a telecommunications provider – CLICK HERE.
In today’s article, the author highlights a new – and little-known – dividend ETF that he believes is a compelling pick for several reasons. The fund in question “selects from the highest yielding dividend stocks in the S&P 500 index, but it uses a different method to add a layer of protection for the dividend….” Moreover, the two factors the fund uses to select stocks are both linked to outperformance. For more on this dividend ETF – including additional ways in which it may be superior to a more well-known option – CLICK HERE.
Out of the nearly 5,000 analysts tracked by the website TipRanks, the five who give their top stock picks for 2018 in today’s article have the most profitable track records based on “the average return and success rate of their buy-sell recommendations over the last year.” So which five specific stocks do these top Wall Street minds see outperforming in the coming year, how much upside do they see for them – and why? CLICK HERE.
“Want to avoid the Spring Slump? All you have to do is follow the leaders,” states the author of today’s article, who notes that, while the S&P 500 has experienced a slump of sorts of late, those stocks that were outperforming at the beginning of the year continue to do so – and are likely to continue doing so going forward. So what are these leaders? The author highlights four outperforming stocks to consider. To find out what these four stocks are – a blue chip healthcare giant, a cosmetics manufacturer, a consumer electronics retailer and an industrial company – CLICK HERE.